Ginkgo Bioworks Holdings Inc (N:DNA)

Business Focus: Biotechnology & Medical Research

Apr 16, 2024 07:02 am ET
Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products
IGDI will leverage Ginkgo's Adaptive Laboratory Evolution technology to improve its sourdough starter culture product
Apr 11, 2024 07:01 am ET
Ginkgo Bioworks Announces Acquisition of AgBiome's Platform Assets
BOSTON, April 11, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of AgBiome's platform assets, including over 115,000 fully sequenced and isolated strains, over 500 million unique gene sequences, and relevant functional data and metadata, as well as AgBiome's development pipeline. These assets will be integrated into Ginkgo Ag Biologicals Services, established with the acquisition of a Bayer agricultural biologicals R&D facility in 2022, and will expand Ginkgo's proprietary un
Apr 11, 2024 07:01 am ET
Ginkgo Bioworks Previews Today's Annual Ferment Conference, Announces "Lab Data as a Service"
BOSTON, April 11, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its 5th annual Ferment conference. The conference brings together stakeholders from across the synthetic biology community, including R&D leaders, Ginkgo Technology Network partners, experts from across academia, journalists, and many more. Because the event has reached its in-person capacity limits, a livestream will be available on Ginkgo's YouTube page and Ginkgo's Investor Relations page.
Apr 10, 2024 07:02 am ET
Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&D Value Chain
BOSTON, April 10, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is developing the leading platform for cell programming and biosecurity, today announced the expansion of its strategic partnership with global healthcare leader Novo Nordisk under a framework agreement that initially is contemplated to run over five years. 
Apr 10, 2024 07:01 am ET
Ginkgo Bioworks Awarded Grant for AI-enabled Forecasting of Measles Outbreaks
Ginkgo epidemiological modeling experts and Northeastern University researchers awarded new grant from the Bill & Melinda Gates Foundation
Apr 08, 2024 07:00 am ET
IdeeLab Joins the Ginkgo Technology Network to Provide Agriculture Companies in Brazil with End-to-End Product Development & Manufacturing Service
Ginkgo customers will now have access to IdeeLab's local strain discovery capabilities, as well as the ability to manufacture next-generation products in IdeeLab's manufacturing facilities
Apr 04, 2024 07:01 am ET
Ginkgo Bioworks to Host 5th Annual Ferment Conference
BOSTON, April 4, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its annual conference, Ferment, on Thursday, April 11, 2024 in Boston, MA. The conference brings together stakeholders from across the synthetic biology ecosystem and the Ginkgo community, from shareholders and customers to suppliers, academics, and many more.
Apr 03, 2024 07:02 am ET
Prozomix and Ginkgo Bioworks Collaborate on Next-Gen Enzyme Development for Sustainable API Manufacturing
The partnership combines Ginkgo's AI/ML and enzyme engineering expertise with Prozomix's wealth of enzyme sequence data to create best-in-class enzymes for API manufacturing
Apr 02, 2024 07:02 am ET
Ginkgo Bioworks Acquires Modulus Therapeutics' Cell Therapy Assets to Strengthen Next-Gen CAR Designs
BOSTON, April 2, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Modulus Therapeutics' cell therapy platform assets, including their chimeric antigen receptor (CAR) and switch receptor libraries.
Mar 28, 2024 07:02 am ET
Ginkgo Bioworks Awarded DARPA Funding to Produce Novel Proteins to Control Ice in Extreme Cold Weather Environments
BOSTON, March 28, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has been awarded a contract for up to $6 million from the Defense Advanced Research Projects Agency (DARPA) to achieve DARPA's objectives under its new Ice Control for cold Environments (ICE) program.
Mar 27, 2024 07:02 am ET
AQUA Cultured Foods Partners with Ginkgo Bioworks to Optimize Alt-Seafood Production
The partners will work to optimize AQUA Cultured Foods' fermentation technology and advance the development and production of AQUA's 100% fish-free products that emulate the look, feel, and taste of fresh-caught seafood
Mar 26, 2024 07:02 am ET
Imagindairy and Ginkgo Bioworks Collaborate to Develop and Produce Animal-Free Non-Whey Dairy Proteins
Imagindairy and Ginkgo will leverage Ginkgo Protein Expression Services and Imagindairy's process development and scale-up expertise to economically produce non-whey dairy proteins for the food industry, funded in part by a competitively won joint grant by the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation
Mar 12, 2024 07:00 am ET
CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, the Centers for Disease Control and Prevention (CDC), and XpresCheck by XWELL, Inc. (Nasdaq: XWEL), a leader in the delivery of onsite...
Feb 28, 2024 07:12 am ET
bit.bio Announced as Inaugural Partner of Ginkgo Bioworks’ New Technology Network
bit.bio, the company coding human cells for novel cures, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced bit.bio as an inaugural partner of the Ginkgo Technology Network. The Network, launched today, is a groundbreaking ecosystem of cutting edge technology partners, committed to collaborating with Ginkgo to provide new, integrated capabilities to drive success in customer R&D programs.
Feb 27, 2024 06:05 am ET
Ginkgo Bioworks Announces Participation in the 44th Annual TD Cowen Health Care Conference
BOSTON, Feb. 27, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is scheduled to participate in Cowen's 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 2:10 p.m. ET.
Feb 22, 2024 06:00 am ET
Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2023 Results Presentation
Presentation and Q&A session scheduled for post-market on Thursday, February 29, 2024
Feb 15, 2024 06:02 am ET
Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design
BOSTON and LEXINGTON, Mass., Feb. 15, 2024 /PRNewswire/ -- The Defense Threat Reduction Agency's (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program has awarded, through the Medical CBRN [Chemical, Biological, Radiological, and Nuclear] Defense Consortium (MCDC) requirement 22-05, "Adjuvant Activity to Vaccines Prototype," a 5-year contract totaling up to $31 million including program options to the team of Ginkgo Bioworks, Inc. (NYSE: DNA) and SaponiQx, Inc. (a subsidiary of Agenus Inc., NASDAQ:AGEN) to discover and develop next-generation
Feb 13, 2024 06:01 am ET
House Select Committee Tours Ginkgo Bioworks, Previews Biofab1, Ginkgo's New Integrated Data Generation Facility Set to Launch in 2025
Members of Congress visited Ginkgo's Boston Seaport headquarters to discuss strategies for bolstering U.S. ability to compete in AI applications for biotechnology, as well as unlocking innovations in pharmaceuticals, agriculture, and across industriesGinkgo's Foundry generates essential data assets and tools to allow companies to more reliably develop biotech products Members also previewed Ginkgo's new Biofab1 facility, under construction in the Seaport, which is expected to significantly increase Ginkgo's R&D-for-service capacities when fully operationalGinkgo's facilities in Boston en
Feb 01, 2024 06:00 am ET
Bioluminescent Plants Are Now Even Brighter: Light Bio to Begin Selling Firefly Petunias to Consumers with USDA Approval
KETCHUM, Idaho, Feb. 1, 2024 /PRNewswire/ -- Light Bio, an innovative synthetic biology startup, today announced that it is beginning to sell its groundbreaking bioluminescent petunias in the United States. With support from notable biotech leaders such as NFX and Ginkgo Bioworks (NYSE: DNA), Light Bio is reimagining the horticultural industry by introducing a new category of plants that emit an ethereal glow to enrich homes, gardens, and public spaces.
Jan 31, 2024 06:00 am ET
Phytolon and Ginkgo Bioworks Successfully Achieve First Milestone to Produce Vibrant Natural Food Colors via Two Producing Strains
This first milestone has made the full color palette of the yellow-to-purple spectrum accessible for Phytolon's food colors and has further established a unique and cost-efficient offering for the food industryPhytolon's natural betalain pigments, produced through fermentation-based technologies, offer safe, sustainable alternatives to synthetic dyes, addressing growing regulatory concerns and consumer demand for natural productsGinkgo Natural Product Services played a crucial role in enhancing the efficiency of Phytolon's yeast strains, ensuring the consistent and robust production of susta
Jan 15, 2024 06:00 am ET
Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world
The companies plan to join forces to set up pathogen monitoring programs utilizing Illumina technology across Concentric's global network 
Jan 10, 2024 06:35 am ET
Ginkgo Bioworks Provides Business Updates at J.P. Morgan Healthcare Conference
Expects to meet 2023 new program and revenue guidance ranges
Jan 08, 2024 08:31 am ET
Thinking about buying stock in Spectaire Holdings, Dorian LPG, Ginkgo Bioworks, Dada Nexus, or Ampio Pharmaceuticals?
NEW YORK, Jan. 8, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPEC, LPG, DNA, DADA, and AMPE.
Jan 08, 2024 06:00 am ET
Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board
BOSTON, Jan. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the formation of its new Biopharma Advisory Board.
Jan 04, 2024 06:00 am ET
Ginkgo Bioworks Completes Program with Biogen to Boost Productivity of Gene Therapy Manufacturing Platform
Collaboration enhanced the productivity of Biogen's AAV production platform to help accelerate efforts to bring novel gene therapies to patients worldwide
Jan 03, 2024 06:00 am ET
Ginkgo Bioworks Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 3, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45 a.m. PT (12:45 p.m. ET).
Dec 20, 2023 06:00 am ET
OneOne Biosciences Partners with Ginkgo Bioworks to Advance its Platform and Nitrogen Fixation Microbial Product
OneOne is a French biotech startup developing a comprehensive suite of agricultural microbial solutionsGinkgo will support OneOne in its agricultural biologicals and synthetic biology R&DGinkgo will initially conduct in vitro and in planta assays to test OneOne's concept. In a planned second phase, Ginkgo's Strain Optimization Services and ultra high throughput encapsulated screening will provide OneOne with optimized strains for nitrogen fixationOneOne expects to use those strains to move to field trials and minimize its time-to-marketPARIS and BOSTON, Dec. 20, 2023 /PRNewswire/ -- OneO
Dec 19, 2023 06:01 am ET
FGen AG, a Ginkgo Bioworks Subsidiary, Awarded Funding Through European Innovation Council's Pathfinder Programme For Sustainable Milk Protein Production Project
The EIC has tapped FGen and partners to work on developing a sustainable, alternative approach to milk production using only CO2 and electricityFGen will focus on ultra-high throughput screening of bacteria engineered to convert CO2 into a major whey proteinUtilizing microbial systems — instead of livestock — to produce valuable food ingredients will be critical for sustainable bioproduction of foods, medicines, and chemicalsBASEL, Switzerland, Dec. 19, 2023 /PRNewswire/ -- FGen AG, a subsidiary of Ginkgo Bioworks (NYSE: DNA), based in Switzerland, has been awarded funding through the Europe
Dec 19, 2023 06:01 am ET
GreenLab Selects Ginkgo Enzyme Services to Develop Novel Enzyme That Breaks Down 'Forever Chemicals'
GreenLab is creating an enzymatic solution — to be grown and scaled within corn plants — to degrade PFAS, often called "forever chemicals," a major health and environmental concernGinkgo has been tapped to discover and develop an enzyme that will be critical to the success of GreenLab's PFAS degradation applicationThrough a partnership with Allonnia, this project is the first step in a path that could potentially lead to the first-ever commercially deployed enzymatic solution for PFAS degradationJONESBORO, Ark. and BOSTON, Dec. 19, 2023 /PRNewswire/ -- GreenLab, an emerging next generation p
Dec 19, 2023 06:01 am ET
U.S. Department of Energy Awards Team Led by Ginkgo Bioworks Funding to Develop Algal Crop Protection Solutions
Algae-based biotechnology can be used to drive forward clean energy solutions, such as sustainable aviation fuel, yet scaling algal biotechnologies for such purposes faces major barriersThe DOE has awarded a Ginkgo-led team — which also includes partners from Pacific Northwest National Laboratory, Colorado School of Mines, and Global Algae Innovations — to build revolutionary algal crop protection solutionsThe team will leverage its expertise in applied algal biology, metagenomics, high-throughput screening, and adaptive laboratory evolution to work to design algal crop protection solutions
Dec 13, 2023 06:01 am ET
Ginkgo Bioworks Receives Grant to Develop Innovative Live Cell Delivery Platform of Antibody Therapeutics for Treating HIV and Malaria
Ginkgo, under a grant from the Bill & Melinda Gates Foundation, will work to develop a live cell therapeutic that can produce antibodies to fight human immunodeficiency virus (HIV) and/or malaria directly in the bodyGinkgo will apply its cell engineering expertise towards creating a fundamentally new cell-based therapeutic delivery modality which could change the future of biologics delivery in medicineBOSTON, Dec. 13, 2023 /PRNewswire/ -- – Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, has received a grant from the Bill & M
Dec 12, 2023 06:01 am ET
Arbor Biotechnologies Announces Collaboration with Ginkgo Bioworks to Advance the Discovery and Development of Precision Gene Editors
Arbor, a biotechnology company discovering and developing the next generation of genetic medicines, will leverage Ginkgo's R&D services to further optimize Arbor's novel precision editorsArbor's portfolio of novel gene editors has significant therapeutic potential because of their unique protospacer adjacent motifs, varied cut types, smaller editing technology, and high specificityGinkgo's high-throughput Mammalian Foundry enables companies like Arbor to optimize novel gene editors with improved functional characteristics by screening in mammalian cellsCAMBRIDGE, Mass. and BOSTON, Dec. 1
Dec 08, 2023 06:02 am ET
Agrivalle and Ginkgo Bioworks Enter Multiyear Strategic Partnership to Accelerate Next-Gen Ag Biological Products
SÃO PAULO and BOSTON, Dec. 8, 2023 /PRNewswire/ -- Agrivalle, a leading Brazilian agricultural biologicals company, today announced a new partnership with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity. Together, the companies will collaborate on building cutting edge technologies to advance Agrivalle's biological products, including next-gen fertilizers and biocontrol agents.
Dec 06, 2023 04:00 pm ET
Synplogen and Ginkgo Bioworks Announce Plans to Accelerate Global DNA Manufacturing and Gene Therapy Platform Services in Japan
Synplogen, a synthetic biology startup spun out of Kobe University's Graduate School of Science, Technology and Innovation that provides custom DNA synthesis and Gene Therapy Biofoundry™ services, has entered into a non-binding Memorandum of Understanding ("MOU") with Ginkgo Bioworks with the intent to advance global DNA manufacturing and gene therapy platform services within the Japanese marketSynplogen intends to support and introduce Ginkgo's gene therapy services within the Japanese biotechnology and pharmaceutical ecosystemKOBE, Japan and BOSTON, Dec. 6, 2023 /PRNewswire/ -- Synplogen C
Nov 27, 2023 06:00 am ET
Vivici Selects Ginkgo Bioworks to Extend Their Range of Novel Dairy Proteins
Vivici has formed a partnership with Ginkgo to advance production of a sustainable and nutritious dairy protein, made via precision fermentation.Ginkgo will use its Protein Production Services and generative AI platform to deliver best-in-class candidate strains to Vivici.Vivici will use the strains from this collaboration to extend their existing range of proteins, supporting innovative specialized nutrition companies, to bring planet-friendly nutrition to consumers.DELFT, Netherlands and BOSTON, Nov. 27, 2023 /PRNewswire/ -- Vivici BV, an innovative B2B ingredients startup company using pr
Nov 27, 2023 02:51 am ET
Vivici Selects Ginkgo Bioworks to Extend Their Range of Novel Dairy Proteins
Vivici has formed a partnership with Ginkgo to advance production of a sustainable and nutritious dairy protein, made via precision fermentation.Ginkgo will use its Protein Production Services and generative AI platform  to deliver best-in-class candidate strains to Vivici.Vivici will use the strains from this collaboration to extend their existing range of proteins, supporting innovative specialised nutrition companies, to bring planet-friendly nutrition to consumers.DELFT, Netherlands and BOSTON, Nov. 27, 2023 /PRNewswire/ -- Vivici BV, an innovative B2B ingredients startup company using p
Nov 14, 2023 04:30 pm ET
XWELL, Inc. Reports Third Quarter 2023 Results
XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today reported results for the third quarter ended September 30, 2023. Financial and Business Highlights: The Company’s airport...
Nov 09, 2023 06:01 am ET
Foremost Farms Selects Ginkgo Bioworks to Develop Technology for Upcycling Dairy Co-products
Foremost aims to commercialize a technology that can convert dairy manufacturing co-products into environmentally friendly, value-added materialsThe partners aim to reduce the dairy industry's carbon footprint while simultaneously lowering manufacturing costs and creating a significant new revenue stream for the hundreds of Midwest dairy farmer members comprising the Foremost Farms cooperative Foremost Farms will leverage Ginkgo's bioproduction services and market-leading metabolic engineering and analytical capabilities to advance this novel technologyMIDDLETON, Wis. and BOSTON, Nov. 9, 202
Nov 08, 2023 04:01 pm ET
Ginkgo Bioworks Reports Third Quarter 2023 Financial Results
Ginkgo added 21 new Cell Programs to the Foundry platform in Q3 2023
Nov 06, 2023 07:00 am ET
Ginkgo Bioworks and XWELL Implement Expanded CDC Traveler-based Genomic Surveillance Program to Test for More than 30 Known Pathogens
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and XWELL, Inc. (Nasdaq: XWEL) today announced they are expanding their work with the U.S. Centers for Disease Control and Prevention's...
Nov 06, 2023 06:00 am ET
Ginkgo Bioworks and XWELL Implement Expanded CDC Traveler-based Genomic Surveillance Program to Test for More than 30 Known Pathogens
The program can be an effective early warning system for public health and national security officials, leveraging voluntary nasal and wastewater sampling from international travelers at major U.S. airports
Nov 01, 2023 07:00 am ET
Ginkgo Bioworks Announces Date of Third Quarter 2023 Results Presentation
Presentation and Q&A session scheduled for post-market on Wednesday, November 8, 2023
Oct 24, 2023 07:00 am ET
Concentric by Ginkgo Partners with Penn State University on Zoonotic Disease Biosurveillance Research Supported by USDA Grant
The grant will fund research into more than 50 species of wildlife to better monitor for and prevent biological threats to humans
Oct 23, 2023 09:31 am ET
Thinking about buying stock in XORTX Therapeutics, Tempest Therapeutics, Ginkgo Bioworks Holdings, Athersys, or Textainer Group Holdings?
NEW YORK, Oct. 23, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XRTX, TPST, DNA, ATHX, and TGH.
Oct 20, 2023 09:31 am ET
Thinking about buying stock in AGNC Investment, Lithium Americas, VinFast Auto, Athersys, or Ginkgo Bioworks Holdings?
NEW YORK, Oct. 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGNC, LAC, VFS, ATHX, and DNA.
Oct 19, 2023 04:01 pm ET
Government of Serbia and Ginkgo Bioworks Announce Bioeconomy Collaboration in BIO4 Campus
BELGRADE, Serbia and BOSTON, Oct. 19, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Government of Serbia today announced that they have entered into a Memorandum of Understanding ("MoU") with the intent of collaborating in support of Serbia's bioeconomy vision.
Oct 17, 2023 07:01 am ET
Persephone Biosciences and Ginkgo Bioworks Complete Reusable Bacteroides Anaerobic Engineering Toolkit
- Persephone to utilize the Bacteroides technology for the rapid generation of therapeutics from its planned and ongoing biomarker studies, including the ARGONAUT study
Oct 16, 2023 09:31 am ET
Thinking about buying stock in Ginkgo Bioworks Holdings, Ambrx Biopharma, Uranium Royalty Corp, Frontline Plc, or Femasys?
NEW YORK, Oct. 16, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DNA, AMAM, UROY, FRO, and FEMY.
Oct 16, 2023 07:01 am ET
Zenfold Leverages Ginkgo Enzyme Services to Enable Veterinary Active Ingredient Development with Sustainable Biology
BOSTON, Oct. 16, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and Zenfold Sustainable Technologies, a company focused on developing and manufacturing specialty ingredients using sustainable technologies and precision fermentation, today announced a collaboration to leverage Ginkgo Enzyme Services in its effort to discover an enzyme critical to the manufacturing of veterinary products. This partnership aims to replace traditional chemical processes in veterinary active ingredient production with a sustainable bi
Oct 12, 2023 07:01 am ET
QL AG Announces Partnership with Ginkgo Bioworks to Develop Dairy Proteins
ZURICH, Switzerland and BOSTON, Oct. 12, 2023 /PRNewswire/ -- QL AG, an innovative food technology solutions company, today announced a new collaboration to develop dairy proteins with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity. QL AG will tap into Ginkgo's extensive capabilities in strain engineering across multiple chassis organisms to support its goal of providing the market with high-quality nutritionally equivalent dairy proteins.
Oct 05, 2023 07:00 am ET
Concentric by Ginkgo to Support CDC-Funded Consortium to Develop New AI-Based Technologies for Epidemic Forecasting
Led by Northeastern University, the EPISTORM center will prepare local communities and hospitals for future outbreaks
Oct 02, 2023 07:01 am ET
Nosh.bio Leverages Ginkgo Strain Optimization Services to Enhance Meaty Taste of Mycoprotein
BOSTON and BERLIN, Oct. 2, 2023 /PRNewswire/ -- Nosh.bio, a German startup developing highly functional ingredients from fungal biomass for animal-free food products, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. Nosh.bio will leverage Ginkgo Strain Optimization Services to screen for protein-producing fungi strains with superior sensorial profiles. By leveraging Ginkgo's ultra high throughput encapsulated screening capabilities, the program aims to produce a mycoprotein that delivers a rich, s
Sep 29, 2023 07:00 am ET
Concentric By Ginkgo and Texas A&M University Awarded USDA NIFA AFRI Grant to Conduct Genomic Animal Research to Prevent Zoonotic Disease Spillover
The grant will fund research of white-tailed deer to evolve knowledge of spillover events and support efforts to design an early warning system for biological threats
Sep 28, 2023 07:01 am ET
Ensovi Leverages Ginkgo Enzyme Services to Optimize Cell-Free Carbon Fixation Process for Biomanufacturing
BOSTON, Sept. 28, 2023 /PRNewswire/ -- Ensovi Inc., which has invented an efficient, cell-free biomanufacturing platform that transforms waste CO2 to organic chemicals, today announced a new partnership with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity. Ensovi will leverage Ginkgo Enzyme Services to help optimize its platform for the cell-free transformation of carbon dioxide (CO2) into Acetyl-CoA, which can then be converted into many other products, such as precursors to flavorings, supplements, pharmaceuticals or even fuels, usin
Sep 27, 2023 07:01 am ET
Ginkgo Bioworks Announces Multi-Target RNA Discovery Collaboration with Pfizer
BOSTON, Sept. 27, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug candidates. In the collaboration, Pfizer will leverage Ginkgo's proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas. Ginkgo will receive an upfront payment and is eligible to receive research fees and development and commercial milestone payments, up to an aggregate total of $331 million across three programs. Ginkgo is entitled to potential further downstream
Sep 25, 2023 07:00 am ET
Ginkgo Bioworks and the Government of the Republic of Madagascar Announce Plans to Develop New Biosecurity Capabilities
ANTANANARIVO, Madagascar and BOSTON, Sept. 25, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Government of the Republic of Madagascar today announced that they have entered into a Memorandum of Understanding ("MOU") with the intent to develop and implement new biosecurity capabilities in Madagascar.
Sep 18, 2023 07:01 am ET
Factorial Biotechnologies and Ginkgo Bioworks Partner To Develop Enzyme for Single-Cell Library Prep Technology
SAN CARLOS, Calif. and BOSTON, Sept. 18, 2023 /PRNewswire/ -- Factorial Biotechnologies, an emerging single-cell sequencing company with a novel intracellular library preparation technology, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new collaboration. Through this partnership, Factorial will leverage Ginkgo Enzyme Services to develop a novel isothermal DNA polymerase for use in Factorial's single-cell next-generation sequencing (NGS) library prep kit. Given its extensive expertise in this space, Ginkgo is p
Sep 12, 2023 07:00 am ET
Ceres Nanosciences and Ginkgo Bioworks Partner to Bring Pathogen Monitoring Capabilities to Labs Around the World
MANASSAS, Va. and BOSTON, Sept. 12, 2023 /PRNewswire/ -- Ceres Nanosciences, a global leader in developing wastewater testing methods based on its Nanotrap® technology, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that they are partnering to bring pathogen monitoring capabilities to laboratories around the world. Pathogen monitoring and analysis capabilities, including in wastewater, are designed to help public health institutions address regional biosecurity challenges.
Aug 09, 2023 06:21 pm ET
SHAREHOLDER ALERT: Morris Kandinov Investigating CVNA, DNA, NLTX, and PEGA; Shareholders are Encouraged to Contact the Firm
National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Carvana Co., Ginkgo Bioworks Holdings, Inc., Neoleukin Therapeutics, Inc. and Pegasystems Inc.   If you are a current owner of shares of any of...
Aug 02, 2023 07:00 am ET
Ginkgo Bioworks Announces Date of Second Quarter 2023 Results Presentation
Presentation and Q&A session scheduled for post-market on Wednesday, August 9, 2023
Jul 19, 2023 07:01 am ET
Ginkgo Bioworks Awarded DARPA Contract to Reimagine the Manufacturing of Complex Therapeutic Proteins
ARLINGTON, Va. and BOSTON, July 19, 2023 /PRNewswire/ -- Approved for Public Release, Distribution Unlimited — The Defense Advanced Research Projects Agency (DARPA) announced that Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, has been awarded a 4-year contract worth up to $18 million to reimagine how to manufacture complex therapeutic proteins. As a performer on DARPA's Reimagining Protein Manufacturing (RPM) project, Ginkgo aims to deliver revolutionary advances in on-demand protein manufacturing by leveraging Cell-Free Protein Syn
Jul 18, 2023 07:01 am ET
Ginkgo Bioworks and Sumitomo Chemical Announce Expanded Partnership To Develop Functional Chemicals with Synthetic Biology
TOKYO and BOSTON, July 18, 2023 /PRNewswire/ -- Sumitomo Chemical Co., Ltd (TSE:4005), one of Japan's leading chemical companies, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new program to develop functional chemicals with synthetic biology and expand upon the companies' existing biomanufacturing partnership.
Jul 17, 2023 07:00 am ET
Ginkgo Bioworks and the Ministry of Health of the Republic of Botswana Announce Pathogen Monitoring Program at Key Ports of Entry
BOSTON and GABORONE, Botswana, July 17, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Ministry of Health ("MoH") representing the Government of the Republic of Botswana today announced a pathogen monitoring program at key ports of entry to identify new and emerging variants of SARS-CoV-2.
Jul 13, 2023 07:01 am ET
IARPA Awards B24IC Research Contract to Ginkgo Bioworks to Develop Breakthrough Biointelligence and Biosecurity Innovations
BOSTON, July 13, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, has been awarded a research contract from the Intelligence Advanced Research Projects Activity (IARPA), the research and development arm of the U.S. Intelligence Community, for the Biointelligence and Biosecurity for the Intelligence Community (B24IC) program. Through this program, Ginkgo aims to develop a biosensor that records time-ordered cellular memory for improved traceability and biosecurity.
Jul 11, 2023 07:01 am ET
Ginkgo Bioworks Advances Collaboration with Novo Nordisk on Expression Systems for Pharmaceutical Products
BOSTON, July 11, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the pilot phase of their previously announced partnership with Novo Nordisk, a leading global healthcare company, to develop expression systems for pharmaceutical products. With the pilot phase completed and the first milestone achieved, the two companies will now move into the development phase to work towards making a more effective production process. Achievement of the first milestone included extensive modificat
Jun 29, 2023 07:03 am ET
Ambrosia Bio Leverages Ginkgo Enzyme Services to Develop a More Scalable Enzymatic Process for Allulose
Ambrosia aims to make the production of allulose, a next-generation sugar replacement, more scalable and affordable
Jun 28, 2023 07:02 am ET
Voodoo Scientific Leverages Ginkgo Enzyme Services to Develop Enzymatic Processing Aid to Eliminate the Harsh "Bite" from Distilled Alcoholic Beverages
LOS ANGELES and BOSTON, June 28, 2023 /PRNewswire/ -- Voodoo Scientific, a company creating capabilities to help distillers deliver meaningful innovation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced Voodoo's plans to leverage Ginkgo Enzyme Services to optimize an enzymatic solution to enable distillers to produce ultra-premium spirit products that are truly smooth. To support the development of the enzyme critical to Voodoo's product, Ginkgo will leverage its extensive protein discovery and design capabilities
Jun 22, 2023 07:00 am ET
Ginkgo Bioworks 2022 Sustainability Report Highlights Progress Towards a More Sustainable and Inclusive Future
The report, Caring at Ginkgo, demonstrates Ginkgo's commitment and contributions to environmental, societal and governance matters
Jun 06, 2023 07:00 am ET
AgBiome Leverages Ginkgo Strain Optimization Services to Optimize Agricultural Biological Pipeline
By leveraging Ginkgo's ultra high throughput encapsulated screening capabilities, AgBiome aims to unlock even higher performance of its microbial strain pipeline
Jun 05, 2023 07:00 am ET
Ginkgo Bioworks Announces Participation in Goldman Sachs 44th Annual Global Healthcare Conference
BOSTON, June 5, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, announced today that management is scheduled to participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference, on June 12, 2023, at 4:40 p.m. PT.
May 25, 2023 07:00 am ET
Ginkgo Bioworks and Centrient Pharmaceuticals Announce Expansion of Partnership Following Success of Initial Project to Bring Sustainable Innovation to the Generic API Space
RIJSWIJK, Netherlands and BOSTON, May 25, 2023 /PRNewswire/ -- Centrient Pharmaceuticals ("Centrient"), the global business-to-business leader in sustainable antibiotics, next-generation statins and anti-fungals, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced they are expanding their existing partnership aimed at broadening Centrient's portfolio of environmentally friendly active pharmaceutical ingredients (APIs), following the success of previous work together.
May 24, 2023 09:00 am ET
SHAREHOLDER ALERT: Morris Kandinov Investigating LTCH, LFST, BRY, and DNA; Shareholders are Encouraged to Contact the Firm
National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Latch, Inc., LifeStance Health Group, Inc., Berry Corporation, and Ginkgo Bioworks Holdings, Inc.   If you are a current owner of shares of any...
May 10, 2023 04:01 pm ET
Ginkgo Bioworks Reports First Quarter 2023 Financial Results
Ginkgo added 13 new Cell Programs to the Foundry platform in Q1 2023
May 09, 2023 07:00 am ET
Octarine Bio and Ginkgo Bioworks Announce Partnership to Produce Natural Colors
COPENHAGEN, Denmark and BOSTON, May 9, 2023 /PRNewswire/ -- Octarine Bio, a synthetic biology company developing new sustainable bio-based ingredients, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a multi-stage partnership focused on compounds in the tryptophan pathway, with the objective of engineering a strain for producing violacein and its derivatives, a naturally occurring bis-indole pigment with potent bioactive properties including anti-microbial, anti-oxidant, and UV protective properties. Although initi
May 08, 2023 07:00 am ET
Ginkgo Bioworks Partners with Boehringer Ingelheim to Develop Breakthrough Therapies for Hard-to-Treat Diseases
BOSTON, May 8, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership with Boehringer Ingelheim. The two companies will leverage Ginkgo's natural product discovery capabilities to accelerate the discovery and development of novel therapeutic molecules to address diseases with high unmet patient needs that are out of reach of conventional drug discovery.
May 05, 2023 07:00 am ET
Ginkgo Bioworks Announces Appointment of Steven P. Coen as Chief Accounting Officer
Mr. Coen brings over 30 years of public accounting and corporate finance leadership experience, most recently as Corporate Vice President and Corporate Controller at Charles River Laboratories
May 04, 2023 07:00 am ET
Ginkgo Bioworks Announces Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
BOSTON, May 4, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced its participation in the 26th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 16-20, in Los Angeles. Ginkgo will present data on its high-throughput screening platform for chimeric antigen receptor (CAR) libraries, which can enable discovery of CAR variants with desired characteristics. This capability has the potential to discover CAR-T therapeutic candidates that are effective against solid tumors.
May 03, 2023 07:00 am ET
Ginkgo Bioworks Announces Date of First Quarter 2023 Results Presentation
Presentation and Q&A session scheduled for post-market on Wednesday, May 10, 2023
Apr 24, 2023 07:00 am ET
Visolis and Ginkgo Bioworks Announce Partnership to Improve Microbial Strain for Bio-Isoprene and Sustainable Aviation Fuel Production
Partnership aims to enable cost-effective decarbonization of rubber tire manufacturing and sustainable aviation fuel production
Apr 19, 2023 07:00 am ET
Ginkgo Bioworks Previews Today's Annual Ferment Conference
BOSTON, April 19, 2023 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its annual conference, Ferment. The conference brings together stakeholders from across the synthetic biology community, including customers, suppliers, academics, journalists, and many more. Because the event has reached its in-person capacity limits, a livestream will be available on Ginkgo's YouTube page and Ginkgo's Investor Relations page.
Apr 18, 2023 05:00 am ET
Cambrium and Ginkgo Bioworks Complete Successful Collaboration on Data-Driven Cell Factory Engineering
BERLIN and BOSTON, April 18, 2023 /PRNewswire/ -- Cambrium, a leading German start-up focused on the application of generative AI to protein design and synthesis, and Ginkgo Bioworks (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced the successful completion of their collaboration. Through the partnership, Cambrium and Ginkgo combined their capabilities to enable the rapid and cost-effective design of high performing, industrially relevant microbes for protein production.
Apr 17, 2023 07:00 am ET
Ginkgo Bioworks and Syngenta Seeds Announce Collaboration to Develop New Traits for the Next Generation of Seed Technology
Partnership will leverage Ginkgo's cell programming capabilities to support Syngenta's ongoing seeds R&D pipeline efforts
Apr 14, 2023 07:00 am ET
Ginkgo Bioworks and the Government of the Democratic Republic of the Congo Announce Plans to Develop and Implement New Biosecurity Capabilities in the Region
BOSTON and KINSHASA, Democratic Republic of the Congo, April 14, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading horizontal platform for cell programming and biosecurity, and the Institut National de la Recherche Biomédicale ("INRB"), the national medical research organization of the Democratic Republic of the Congo ("DRC"), today announced that they have entered into a Memorandum of Understanding ("MOU") with the intent of developing and implementing new biosecurity capabilities in Democratic Republic of the Congo.
Apr 13, 2023 07:00 am ET
Ginkgo Bioworks and WARF Announce Partnership to Discover Next Generation GD2 CAR T-Cell Therapies
Collaboration with University of Wisconsin Professors Krishanu Saha (PI) and Christian Captini (co-PI) to discover novel and improved GD2 CAR designs to treat solid tumors and validate them in vivo
Apr 12, 2023 07:00 am ET
Ginkgo Bioworks to Host Annual Ferment Conference
BOSTON, April 12, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its annual conference, Ferment, on Wednesday, April 19, 2023 in Boston, MA. The conference brings together stakeholders from across the synthetic biology ecosystem and the Ginkgo community, from shareholders and customers to suppliers, academics, and many more.
Apr 06, 2023 07:00 am ET
Sensible Biotechnologies Raises $4.2mn in a Pre-Seed Financing Round to Revolutionize mRNA Manufacturing
Sensible Biotechnologies aims to build a cell-based platform for cost-efficient and scalable manufacturing of high-quality mRNA.Proceeds will be used to optimize and scale Sensible's mRNA manufacturing platform and mRNA design capabilities.The pre-seed funding led by BlueYard Capital follows Sensible's announcement of a strategic partnership with Ginkgo Bioworks (NYSE: DNA).OXFORD, England, April 6, 2023 /PRNewswire/ -- Sensible Biotechnologies, Inc., an mRNA platform company, has announced a $4.2mn pre-seed round to accelerate the development of its cell-based platform for cost-efficient ma
Apr 05, 2023 07:00 am ET
Ginkgo Bioworks Strengthens End-to-End R&D Capabilities in Gene Therapy through Acquisition of StrideBio's AAV Capsid Discovery and Engineering Platform Assets
Platform includes large library of existing capsids, which have been optimized for performance and targeting across a range of application areas through validation in large animal models
Apr 04, 2023 07:00 am ET
Solvay Announces Strategic Collaboration With Ginkgo Bioworks And Expands Its R&I Footprint In The United States
The investment will accelerate the development of new sustainable biopolymers, strengthening Solvay's position in biotechnology in this important growth platform.
Apr 03, 2023 07:00 am ET
Sensible Biotechnologies Announces Partnership with Ginkgo Bioworks to Develop Novel mRNA Manufacturing Platform
Through this partnership, Sensible and Ginkgo aim to develop an in vivo alternative to conventional in vitro mRNA production technology
Mar 29, 2023 09:00 am ET
SHAREHOLDER ALERT: Morris Kandinov Investigating PRVB, MAXR, DNA, and FOX; Shareholders are Encouraged to Contact the Firm
National law firm Morris Kandinov is investigating Provention Bio, Inc., Maxar Technologies Inc., Ginkgo Bioworks Holdings, Inc., and Fox Corporation. If you are a current owner of shares, contact [email protected] or call (619) 780-3993 to speak with...
Mar 27, 2023 09:00 pm ET
Bragar Eagel & Squire is Investigating Certain Officers and Directors of C3.ai, Ginkgo Bioworks, and Polished on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors C3.ai, Inc. (NYSE: AI), Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), and Polished.com, Inc. (NYSEAmerican: POL) on...
Mar 25, 2023 12:33 am ET
GINKGO BIOWORKS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Ginkgo Bioworks Holdings, Inc. - DNA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Ginkgo Bioworks Holdings, Inc. (NYSE: DNA).
Mar 01, 2023 09:00 pm ET
GINKGO BIOWORKS ALERT: Bragar Eagel & Squire, P.C. is Investigating Ginkgo Bioworks Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) on behalf of long-term stockholders following a class action complaint that was...
Feb 28, 2023 07:30 am ET
Cronos Group Reports 2022 Fourth Quarter and Full-Year Results
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announces its 2022 fourth quarter and full-year business results. “2022 was a transformative year for Cronos in which we executed a business realignment, including a...
Feb 21, 2023 11:43 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ginkgo Bioworks Holdings Inc. (DNA) Investigation
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Soaring Eagle Acquisition Corp., which merged with Ginkgo Bioworks Holdings Inc. ("Ginkgo" or "the Company") (NYSE: DNA) on September 17, 2021. Such investors who continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm’s site:
Feb 16, 2023 06:00 am ET
Zymtronix and Ginkgo Bioworks Announce Partnership to Produce Enzymes for the Industrialization of Cell-Free Biomanufacturing
DURHAM, N.C. and BOSTON, Feb. 16, 2023 /PRNewswire/ -- Zymtronix, a developer of cell-free process technologies, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to optimize enzymes used in Zymtronix's proprietary cell-free platform for the production of important ingredients in food, agriculture, cosmetics and pharmaceuticals.
Feb 06, 2023 03:00 am ET
Feb 01, 2023 03:11 pm ET
SHAREHOLDER ALERT: Morris Kandinov Investigating DNA, APA, LDI and BFLY; Shareholders are Encouraged to Contact the Firm
National law firm Morris Kandinov is investigating Ginkgo Bioworks Holdings, Inc., APA Corporation, loanDepot, Inc., and Butterfly Network, Inc. If you are a current owner of shares, contact [email protected].               Ginkgo Bioworks Holdings,...
Jan 27, 2023 09:00 pm ET
GINKGO BIOWORKS ALERT: Bragar Eagel & Squire, P.C. is Investigating Ginkgo Bioworks Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) on behalf of long-term stockholders following a class action complaint that was filed against Ginkgo Bioworks with a Class Period from May 11, 2021 to October 5, 2021. Our investigation concerns whether the board of directors of Ginkgo Bioworks have breached their fiduciary duties to the company.
Jan 18, 2023 06:00 am ET
NAMUH and Ginkgo Bioworks Announce Partnership to Produce Multiple Infant Nutrition Products
Ginkgo will develop and optimize strains to produce functional oligosaccharides for NAMUH's infant nutrition products
Jan 17, 2023 08:00 am ET
Ginkgo Bioworks and XpresCheck Expand CDC’s Traveler-Based Genomic Surveillance Program to Detect Influenza Variants
Ginkgo Bioworks (NYSE: DNA) and XWELL, Inc. (Nasdaq: XWEL) today announced that they have expanded their support for the Centers for Disease Control and Prevention’s (CDC’s) Traveler-based Genomic Surveillance program to include a pilot study...
Jan 17, 2023 06:00 am ET
Ginkgo Bioworks and the Public Health Center of the Ukraine Ministry of Health Announce Collaboration to Implement Biosecurity Capabilities in Ukraine
The collaboration will launch a pilot program for wastewater-based pathogen monitoring to support critical public health needs
Jan 17, 2023 06:00 am ET
Ginkgo Bioworks and XpresCheck Expand CDC's Traveler-Based Genomic Surveillance Program to Detect Influenza Variants
The program is an effective early warning system for viral variants, leveraging voluntary sampling from international travelers at major U.S. airports
Jan 11, 2023 06:00 am ET
Ginkgo Bioworks Provides Preliminary Unaudited 2022 Revenue Highlights and Business Review
Expects to meet 2022 guidance ranges for Total revenue and new Cell Programs
Jan 09, 2023 06:00 am ET
Prokarium and Ginkgo Bioworks Announce Partnership to Discover Multiple Targets for RNA Therapeutics and Immuno-oncology
LONDON and BOSTON, Jan. 9, 2023 /PRNewswire/ -- Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to develop a bactofection platform to deliver RNA-based therapeutics.
Jan 06, 2023 06:00 am ET
Ginkgo Bioworks Expands Its R&D Facilities, Opens Bioworks7 to Conduct Mammalian Screening at Scale, Widening Capabilities for Biopharma Partners
Newest foundry increases capacity in biopharmaceuticals, biomanufacturing and general mammalian programming for therapeutic applications
Jan 05, 2023 06:00 am ET
Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics
Initial focus of partnership will aim to develop cancer therapeutics
Jan 04, 2023 06:00 am ET
Ginkgo Bioworks Announces Participation in the 41st Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 4, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced today that Co-Founder and CEO Jason Kelly is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 11:15 a.m. PT (2:15 p.m. ET). He plans to discuss Ginkgo's biopharma capabilities and end-to-end services offerings, including Ginkgo Enzyme Services and high throughput pooled screening for CAR-T designs, among other topics.
Dec 20, 2022 06:00 am ET
Ginkgo Bioworks and the Ministry of Health of the Republic of Botswana Announce Plans to Develop and Implement New Biosecurity Capabilities in Botswana
Collaboration aims to leverage innovative biosecurity capabilities to promote public health, global health security, and the development of the bioeconomy
Dec 08, 2022 06:00 am ET
Ginkgo Bioworks Launches Ginkgo Enzyme Services, Enabling Applications across Pharmaceuticals and Diagnostics, Food and Agriculture, and Beyond
Enzyme Intelligence Virtual Event on December 15, 2022 gives overview of Ginkgo's approach to machine learning-guided enzyme engineering
Dec 02, 2022 06:00 am ET
Ginkgo Bioworks Provides Compensation Information Related to Recent Acquisitions
BOSTON, Dec. 2, 2022 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that in connection with its transaction with Bayer CropScience LP ("Bayer") on October 17, 2022, Ginkgo granted 9,868,143 restricted stock units to 139 new employees, and in connection with its acquisition of Zymergen Inc. ("Zymergen") on October 19, 2022, Ginkgo granted 8,305,110 restricted stock units to 179 new employees. The restricted stock units were granted without stockholder approval as material induc
Nov 16, 2022 06:30 am ET
Ginkgo Announces Public Offering of Class A Common Stock
BOSTON, Nov. 16, 2022 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading platform for cell programing and biosecurity, today announced the sale of shares of  its Class A common stock for gross proceeds of approximately $100 million to BTIG, LLC, as the underwriter in the registered public offering of those shares. In connection with this offering, Ginkgo has granted the underwriter a 30-day option to purchase up to an additional $15 million of  shares of Class A common stock.
Nov 15, 2022 03:17 pm ET
Ginkgo Bioworks Announces Proposed Public Offering of Class A Common Stock
BOSTON, Nov. 15, 2022 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"),which is building the leading platform for cell programing and biosecurity, today announced that it intends to offer and sell $100 million of its Class A common stock in an underwritten public offering. As part of this offering, Ginkgo intends to grant the underwriter a 30-day option to purchase up to an additional $15 million of the shares of Class A common stock. All of the shares in the proposed offering are to be sold by Ginkgo.
Nov 14, 2022 03:01 pm ET
Ginkgo Bioworks Reports Third Quarter 2022 Financial Results
15 new Cell Programs added and $66 million of Total revenue in Q3 2022
Nov 11, 2022 06:00 am ET
Lygos and Ginkgo Bioworks Announce Partnership to Optimize Production of Biobased Specialty Chemicals
Strain development program aims to accelerate efforts to create sustainable chemicals
Nov 09, 2022 06:00 am ET
Ginkgo Bioworks To Present New Data on High Throughput Pooled Screening Method to Discover Novel CAR-T Designs for Solid Tumors
Poster presentation at SITC 2022 highlights high throughput methods for discovery of novel CAR designs with improved persistence
Nov 07, 2022 08:25 am ET
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Ginkgo Bioworks Holdings, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK, Nov. 7, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA).
Nov 07, 2022 06:30 am ET
Ginkgo Bioworks Announces Date of Third Quarter 2022 Results Presentation
Presentation and Q&A session scheduled for post-market on Monday, November 14, 2022
Oct 25, 2022 08:45 am ET
Ginkgo Bioworks and the Ministry of Investment of Saudi Arabia Announce Plans to Develop Biosecurity and Biotechnology Capabilities for Global Public Health
Collaboration aims to bolster capabilities of key public health and research institutions, launch new biosecurity initiatives, and drive the development of the bioeconomy
Oct 20, 2022 07:00 am ET
Bolt Threads Announces Latest Collaboration with Ginkgo Bioworks to Optimize its Mylo™ Material
Program builds on the existing relationship between the partners following existing b-silk™ protein optimization project
Oct 19, 2022 09:08 am ET
Ginkgo Bioworks Completes Acquisition of Zymergen
BOSTON and EMERYVILLE, Calif., Oct. 19, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and Zymergen (Nasdaq: ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen. The acquisition is expected to significantly enhance Ginkgo's platform by integrating strong automation and software capabilities as well as a wealth of experience across diverse biological engineering approaches.
Oct 17, 2022 07:00 am ET
IARPA, Ginkgo Bioworks and Draper Announce New Technologies to Detect Engineered DNA
BOSTON, Oct. 17, 2022 /PRNewswire/ -- The Intelligence Advanced Research Projects Activity (IARPA), the research and development arm of the U.S. Intelligence community, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming and Draper, a nonprofit engineering innovation firm, today announced the completion of IARPA's Finding Engineering-Linked Indicators (FELIX) program. The program was created to augment and improve current biodetection and biosurveillance capabilities. Specifically, Ginkgo has developed a suite of new computational tools and Draper has developed
Oct 11, 2022 07:00 am ET
Ginkgo Bioworks Announces Collaboration with Merck to Improve Active Pharmaceutical Ingredient Manufacturing
Ginkgo to engineer key biocatalytic enzymes for potential use in Merck's drug manufacturing processes
Oct 04, 2022 07:01 am ET
Ginkgo Bioworks Acquires Circularis to Strengthen Capabilities in Cell and Gene Therapy
BOSTON, Oct. 4, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the tuck-in acquisition of Circularis, a biotechnology company with a proprietary circular RNA and promoter screening platform. When circularized, RNA is much longer-lived in cells, improving its robustness as a potential therapeutic modality. The Circularis platform also allows ultra-high-throughput screening of promoters and other enhancers. Ginkgo is excited to welcome the Circularis team and platform to enable new solutions across bioproduction, RNA ther
Oct 04, 2022 07:00 am ET
Ginkgo Bioworks Acquires Adaptive Laboratory Evolution Company Altar
BOSTON, Oct. 4, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the tuck-in acquisition of Altar, a French biotechnology company that has developed a proprietary adaptive evolution platform. A fleet of Altar's automated adaptive laboratory evolution (ALE) instruments will be integrated into Ginkgo's Foundry to serve customers across food and beverage, biofuels, biomaterials, cosmetics, animal health and human health applications, among others. Ginkgo has successfully collaborated with Altar on customer programs historica
Sep 20, 2022 10:16 pm ET
ZYMERGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zymergen - ZY
NEW ORLEANS, Sept. 20, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Zymergen Inc. (NasdaqGS: ZY) to Ginkgo Bioworks Holdings, Inc. (NYSE: DNA).  Under the terms of the proposed transaction, shareholders of Zymergen will receive a fixed exchange ratio of 0.9179 Ginkgo shares for each share of Zymergen that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Co
Sep 12, 2022 09:00 am ET
Renee Wegrzyn Slated to Lead New Advanced Research Projects Agency for Health
BOSTON, Sept. 12, 2022 /PRNewswire/ -- The White House today announced that President Biden intends to appoint Renee Wegrzyn, PhD, as the first Director of the Advanced Research Projects Agency for Health (ARPA-H). Dr. Wegrzyn is currently the Vice President for Business Development at Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming. ARPA-H was established in March 2022 to drive transformative health breakthroughs that cannot readily be accomplished through traditional research or commercial activity.
Sep 01, 2022 07:00 am ET
Ginkgo Bioworks Appoints Dr. Behzad Mahdavi as Senior Vice President of Biopharma Manufacturing & Life Science Tools
BOSTON, Sept. 1, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that Behzad Mahdavi, Ph.D., MBA, has joined as senior vice president of biopharma manufacturing and life sciences tools. In this new role, Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities. Dr. Mahdavi brings more than 20 years of experience in developing and leading innovative patient-centric growth strategies in challenging environments in the biopharmaceuti
Aug 24, 2022 09:00 am ET
Ayana Bio Announces Appointment of Frank Jaksch as Chief Executive Officer
Health and wellness industry veteran will lead the company to scale sustainable bioactives using plant cell technology instead of agriculture                                                     
Aug 19, 2022 07:00 am ET
Ginkgo Bioworks Announces Strategic Purchase of Epidemiological Data Infrastructure Assets
Transaction is expected to bolster Ginkgo's growing biosecurity platform and provide expanded epidemic tracking, modeling, and forecasting offerings to public health leaders and communities
Aug 16, 2022 08:30 am ET
Thinking about buying stock in AMTD IDEA Group, Zymergen, Ginkgo Bioworks, Greenbox POS, or IZEA Worldwide?
NEW YORK, Aug. 16, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMTD, ZY, DNA, GBOX, and IZEA.
Aug 15, 2022 04:01 pm ET
Ginkgo Bioworks Reports Second Quarter 2022 Financial Results
$145 million of Total revenue in Q2 2022, representing 231% growth over Q2 2021
Aug 15, 2022 09:00 am ET
Ginkgo Bioworks and XpresCheck Receive Award to Expand CDC’s Traveler-Based SARS-CoV-2 Genomic Surveillance Program In U.S. Airports
Ginkgo Bioworks (NYSE: DNA) and XpresSpa Group, Inc. (Nasdaq: XSPA) announced they will continue to support the Centers for Disease Control and Prevention’s (CDC’s) traveler-based SARS-CoV-2 genomic surveillance program through a new contract...
Aug 15, 2022 08:49 am ET
Ginkgo Bioworks and XpresCheck Receive Award to Expand CDC's Traveler-Based SARS-CoV-2 Genomic Surveillance Program In U.S. Airports
Public-private partnership to enable the development of innovative, sustainable infrastructure designed to set the global standard for travel biosecurity
Aug 11, 2022 11:25 am ET
Thinking about buying stock in T2 Biosystems, AcelRx Pharmaceuticals, Ginkgo Bioworks, BioNano Genomics, or AMC Entertainment?
NEW YORK, Aug. 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTOO, ACRX, DNA, BNGO, and AMC.
Aug 11, 2022 07:05 am ET
Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks
SYNB2081 is the second clinical drug candidate developed through the partnership between Ginkgo and Synlogic
Aug 11, 2022 07:00 am ET
Ginkgo Bioworks and the Rwanda Development Board Announce Plans to Develop and Implement New Biosecurity Capabilities in Rwanda
Collaboration aims to leverage innovative biosecurity capabilities to promote global health security and accelerate the development of the regional bioeconomy
Aug 08, 2022 08:50 am ET
Ginkgo Bioworks Announces Date of Second Quarter 2022 Results Presentation
Presentation and Q&A session scheduled for post-market on Monday, August 15, 2022
Aug 04, 2022 07:00 am ET
Ginkgo Bioworks Appoints Kathy Hopinkah Hannan to its Board of Directors
BOSTON, Aug. 4, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that Kathy Hopinkah Hannan, PhD, CPA has joined its Board of Directors, effective August 2, 2022. Dr. Hannan brings over thirty years of experience as a senior C-Suite executive, corporate advisor, independent board director and strategist leading significant operations and high priority initiatives.
Jul 26, 2022 06:47 pm ET
ZYMERGEN ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of ZY and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Zymergen Inc. (NASDAQ: ZY) (“Zymergen”) breached their fiduciary duties or violated the...
Jul 25, 2022 04:40 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sharps Compliance Corp. (Nasdaq - SMED), Infrastructure and Energy Alternatives, Inc. (Nasdaq - IEA), AutoWeb,
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Jul 25, 2022 07:01 am ET
Ginkgo to Acquire Zymergen
Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platformExpect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end marketsZymergen's core technical team is expected to help fill significant planned hiring by Ginkgo across its cell engineering, automation, digital technology, and data teams, accelerating sc
Jul 25, 2022 07:00 am ET
Ginkgo and Bayer Sign Definitive Agreement to Build Agricultural Biologicals R&D Platform Capabilities
Ginkgo to acquire Bayer's 175,000-square-foot Biologics R&D center and enter into a new multi-year platform collaboration with Bayer to advance several agricultural biological programs
Jul 18, 2022 07:00 am ET
Ginkgo Bioworks Announces Latest Collaboration for Beauty and Personal Care Industry with Sumitomo Chemical
BOSTON, July 18, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the launch of a new cell programming project as part of a broader collaboration with Sumitomo Chemical Co., Ltd (TSE:4005), one of Japan's leading chemical companies. Through this partnership, Sumitomo Chemical will leverage Ginkgo's extensive codebase and expertise in organism engineering to produce molecules in a sustainable fashion that are used in products across a broad range of industries. The target molecule of this latest project is planned to be us
Jul 14, 2022 07:00 am ET
Ginkgo Bioworks Publishes Inaugural Sustainability Report
The report, "Caring at Ginkgo," outlines the company's approach to sustainability, internal governance structures, and how its cell engineering platform is deployed
Jun 27, 2022 08:00 am ET
EATV, the World's First Plant-based Innovation ETF, Makes History at The New York Stock Exchange (NYSE: EATV)
VegTech™ Invest, Advisor to EATV, the VegTech™ Plant-based Innovation & Climate ETF,  throws historic party at The New York Stock Exchange celebrating the EATV listing and world's first Plant-based Innovation ETF, (NYSE: EATV).
Jun 21, 2022 07:00 am ET
Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos"), an innovative global cannabinoid company, and Ginkgo Bioworks (NYSE: DNA) (“Ginkgo”), the leading horizontal platform for cell programming, today announced the achievement of the third target...
Jun 21, 2022 07:00 am ET
Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone
TORONTO and BOSTON, June 21, 2022 /PRNewswire/ -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos"), an innovative global cannabinoid company, and Ginkgo Bioworks (NYSE: DNA) ("Ginkgo"), the leading horizontal platform for cell programming, today announced the achievement of the third target productivity milestone in their partnership to produce eight cultured cannabinoids. Using Ginkgo's platform for organism design and development, Cronos has successfully achieved the productivity target for tetrahydrocannabivarin (THCV), a cannabinoid hypothesized to reduce the appetite-enhancing pr
Jun 10, 2022 04:15 pm ET
Ginkgo Bioworks Announces Participation in Goldman Sachs 43rd Annual Global Healthcare Conference
BOSTON, June 10, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in Goldman Sachs' 43rd Annual Global Healthcare Conference, on June 15, 2022, at 10:40 a.m. PT.
Jun 07, 2022 07:15 am ET
Ginkgo Bioworks and Novo Nordisk to Collaborate on Expression Systems for Pharmaceutical Products
BOSTON, June 7, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration with Novo Nordisk, a leading global healthcare company, to create novel expression hosts for pharmaceutical products.
Jun 06, 2022 07:15 am ET
Ginkgo Bioworks Acquires Bitome, an Integrated Metabolite Monitoring Platform
Through real-time metabolite monitoring, Bitome's technology is expected to support accelerated product development timelines across Ginkgo's portfolio of cell programs
Jun 02, 2022 04:00 pm ET
Ginkgo Bioworks Announces Participation in William Blair's 42nd Annual Growth Stock Conference
BOSTON, June 2, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in William Blair's 42nd Annual Growth Stock Conference, on June 9, 2022, at 11:20 a.m. CT.
May 18, 2022 07:00 am ET
Ginkgo Bioworks and First Serv Announce Plans to Develop and Implement Innovative Global Biosecurity Capabilities in Qatar
Partnership recognizes the importance of global cooperation to prevent and respond to pandemics
May 16, 2022 04:01 pm ET
Ginkgo Bioworks Reports First Quarter 2022 Financial Results
$168 million of Total revenue in Q1 2022, representing an increase of 282% over Q1 2021
May 11, 2022 07:00 am ET
Evo Foods and Ginkgo Bioworks Announce Partnership to Develop Animal-Free Egg Products
Evo Foods will leverage Ginkgo's cell engineering capabilities to explore recombinant production methods for egg proteins
May 09, 2022 07:00 am ET
Ginkgo Bioworks Announces Date of First Quarter 2022 Results Presentation
Presentation and Q&A session scheduled for post-market on Monday, May 16, 2022
Apr 22, 2022 08:00 am ET
Ginkgo Bioworks to Expand Platform Capabilities in Agricultural Biologicals and Launch Flagship Partnership with Bayer
Planned transaction expands Ginkgo's horizontal platform capabilities to support agricultural biologicals R&D from discovery through formulation and early field trials and will offer services to customers of all sizes in the agriculture industry Under the proposed transaction, Ginkgo to acquire Bayer's West Sacramento agricultural biologicals site and team, adding a 175,000-square-foot R&D facility with pilot scale fermentation, formulation, and greenhouse facilities, along with access to Bayer's large agricultural strain collectionJoyn Bio, the joint-venture between Ginkgo and Leaps
Apr 14, 2022 05:00 pm ET
Light Bio Partners with Ginkgo Bioworks to Optimize the Brightness of Glowing Plants through Bioluminescence Engineering
Leveraging Ginkgo's plant-cell assay and engineering capabilities to aid Light Bio in optimizing the performance of its light-emitting plants
Apr 14, 2022 10:55 am ET
Thinking about buying stock in American Airlines, Petroleo Brasileiro, Agile Therapeutics, Uranium Energy, or Ginkgo Bioworks?
NEW YORK, April 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAL, PBR, AGRX, UEC, and DNA.
Apr 13, 2022 03:30 pm ET
Lifshitz Law Firm, P.C. Announces Investigations of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), Lightning eMotors, Inc. (NYSE: ZEV), Owlet, Inc. (NYSE: OWLT), and Peloton Interactive, Inc. (NASDAQ: PT
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) Lifshitz Law PLLC announces that a class action complaint was filed against Ginkgo alleging that Defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose...
Apr 13, 2022 07:00 am ET
FREDsense and Ginkgo Bioworks Announce Partnership to Develop Water Quality Biosensors
FREDsense will leverage Ginkgo's strain development platform capabilities to develop advanced biosensors capable of detecting harmful molecules and toxins in any water source
Apr 12, 2022 07:00 am ET
Persephone Biosciences and Ginkgo Bioworks Announce Collaboration to Develop Novel Therapeutics
Multi-project agreement involves engineering of anaerobic species, a critical component for microbiome medicines
Apr 11, 2022 07:00 am ET
Elanco and Ginkgo Bioworks Launch BiomEdit, a New Animal Health Company Leveraging Microbiome Technology
BiomEdit intends to discover and develop animal health products that leverage microbiome science to improve animal health, animal protein production, and livestock disease monitoring
Apr 05, 2022 07:00 am ET
Twist Bioscience and Ginkgo Bioworks Sign New Collaboration
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and
Apr 04, 2022 05:00 pm ET
Microba Life Sciences and Ginkgo Bioworks Announce Partnership to Discover Novel Live Biotherapeutics
Microba Life Sciences (ASX: MAP), a precision microbiome science company, and
Apr 04, 2022 07:00 am ET
Microba Life Sciences and Ginkgo Bioworks Announce Partnership to Discover Novel Live Biotherapeutics
Partnership will leverage Ginkgo's high throughput screening capabilities to identify potential therapeutic candidates for autoimmune diseases in Microba's extensive strain bank
Mar 29, 2022 09:31 am ET
Thinking about buying stock in Clever Leaves, Grid Dynamics, Aptevo Therapeutics, Ginkgo Bioworks, or Academy Sports and Outdoors?
NEW YORK , March 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLVR, GDYN, APVO, DNA, and ASO.
Mar 29, 2022 08:31 am ET
Thinking about buying stock in Hycroft Mining, Nielsen, Neximmune, 4D pharma, or Ginkgo Bioworks?
NEW YORK, March 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HYMC, NLSN, NEXI, LBPS, and DNA.
Mar 28, 2022 04:01 pm ET
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021 Financial Results
$314 million of Total revenue in 2021, representing an increase of 309% over 2020
Mar 23, 2022 07:00 am ET
CDC, Concentric by Ginkgo and XpresCheck® Publish Results of CDC COVID-19 Air Travel Biosecurity Program at International Airports
The joint, voluntary COVID-19 testing program successfully identified Omicron sublineages BA.2 and BA.3 weeks before the next reported U.S. detections
Mar 17, 2022 08:15 am ET
Mar 15, 2022 07:00 am ET
Ginkgo Bioworks Announces Participation in Jefferies Virtual Synthetic Biology Week
BOSTON, March 15, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in a fireside chat at Jefferies Virtual Synthetic Biology Week, on March 22, 2022, at 10:00 a.m. Eastern Time.
Mar 14, 2022 07:00 am ET
Ginkgo Bioworks Signs Definitive Agreement to Acquire FGen AG, a leading bioengineering company and its proprietary ultra-high-throughput screening platform
BOSTON and BASEL, Switzerland, March 14, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the entry into a definitive agreement to acquire FGen AG ("FGen"), a Swiss company specializing in strain development and optimization. FGen has developed an ultra-high-throughput (uHT) screening platform built on nanoliter reactor technology. Ginkgo believes that FGen's technology will significantly enhance Ginkgo's cell screening capabilities and enable Ginkgo to explore wider expanses of genetic opportunity space, increasing the l
Feb 28, 2022 03:00 am ET
Phytolon and Ginkgo Bioworks Collaborate to Take Biological Production of Vibrant Food Colors to the Next Level
The companies seek to leverage cell programming to produce betalain pigments across the full yellow-to-purple spectrum
Feb 24, 2022 06:00 am ET
Ginkgo Bioworks Announces Participation in Upcoming Conferences
BOSTON, Feb. 24, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in the following upcoming conferences:
Feb 18, 2022 07:30 am ET
Cronos Group Reports 2021 Third Quarter Results
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), today announces its 2021 Third Quarter business results. The Audit Committee of the Company's Board of Directors has completed its evaluation of goodwill and...
Feb 08, 2022 03:00 pm ET
Ginkgo Bioworks Announces Participation in Upcoming Conferences
BOSTON, Feb. 8, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in the following upcoming conferences:
Jan 19, 2022 06:00 am ET
Ginkgo Bioworks Announces Acquisition of Massachusetts COVID-19 Testing Provider Project Beacon COVID-19 LLC
BOSTON, Jan. 19, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the acquisition of Project Beacon COVID-19 LLC (Project Beacon), a Boston-based social benefit organization focused on helping to increase the capacity, availability, accessibility and affordability of COVID-19 testing. Under the terms of the deal, Ginkgo acquired Project Beacon's assets and will assume responsibility for Project Beacon's ongoing operations, providing COVID-19 monitoring tools to communities in Massachusetts and other areas.
Jan 18, 2022 04:32 pm ET
SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ginkgo Bioworks Holdings, Inc. - DNA
Pomerantz LLP is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. (“Ginkgo” or the “Company”) (NYSE: DNA).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Jan 18, 2022 11:00 am ET
DNA; SRNG Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Ginkgo Bioworks Holdings Inc. (f/k/a Soaring Eagle Acquisition Corp.) Investors With Losses Exceeding $200K of Class Action
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ginkgo Bioworks Holdings Inc. (“Ginkgo” or the “Company”) ( NYSE: DNA; SRNG) (f/k/a Soaring Eagle Acquisition Corp.) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Owlet between May 11, 2021, and October 5, 2021, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
Jan 18, 2022 10:16 am ET
FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Ginkgo Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp. Investors to Secure Counsel Before Today’s Important Deadline in Securi
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ginkgo Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp. (NYSE: DNA) (NASDAQ: SRNG) between May 11, 2021 and October 5, 2021, both dates...
Jan 17, 2022 08:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ginkgo Bioworks Holdings, Inc. - DNA
NEW YORK, Jan. 17, 2022 /PRNewswire/ --  Pomerantz LLP is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or the "Company") (NYSE: DNA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jan 17, 2022 08:13 am ET
Final Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed Against Ginkgo Bioworks Holdings, Inc. (DNA)
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Ginkgo Bioworks Holdings, Inc. (“Ginkgo”)...
Jan 17, 2022 05:00 am ET
GINKGO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Ginkgo Bioworks Holdings, Inc. (“Ginkgo” or the “Company”) (NYSE: DNA) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Ginkgo securities between May 11, 2021 and October 5, 2021, both dates inclusive (the “Class Period”). Investors have until January 18, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Jan 14, 2022 11:31 am ET
Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Ginkgo Bioworks Holdings, Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Ginkgo Bioworks Holdings, Inc. (“Ginkgo”) (
Jan 13, 2022 02:04 pm ET
DNA INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces January 18, 2022 Deadline in Securities Fraud Class Action Lawsuit Filed Against of Ginkgo Bioworks Holdings, Inc. Investors
RADNOR, Pa., Jan. 13, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Ginkgo Bioworks Holdings, Inc. ("Ginkgo") (NYSE: DNA) f/k/a Soaring Eagle Acquisition Corp. (NASDAQ: SRNG). The action charges Ginkgo with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Ginkgo's materially misleading statements to the public, Ginkgo investors have suffered significant losses
Jan 13, 2022 01:10 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ginkgo Bioworks Holdings, Inc. - DNA
Pomerantz LLP is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. (“Ginkgo” or the “Company”) (NYSE: DNA).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Jan 12, 2022 06:00 am ET
Ginkgo Bioworks Provides Preliminary Unaudited 2021 Revenue Highlights and Business Review
BOSTON, Jan. 12, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today preliminary performance updates for the year ended December 31, 2021. Among the results, Ginkgo highlighted that it expects to meet or exceed its key 2021 full year targets for the commencement of new cell programs and revenue from its cell programming and biosecurity offerings based on its preliminary unaudited estimates. The results, along with a broader business review, will be featured in a presentation today at the 40th Annual J.P. Morgan Healthcare Co
Jan 11, 2022 10:06 am ET
Z, OWLT & DNA – Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Actions and Upcoming Deadlines
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jan 10, 2022 12:10 pm ET
Jan 10, 2022 08:57 am ET
Final Deadline Approaching on January 18, 2022: Kessler Topaz Meltzer & Check, LLP Reminds Ginkgo Bioworks Holdings, Inc. Investors of Class Action Lawsuit Deadline
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Ginkgo Bioworks Holdings, Inc. (“Ginkgo”)...
Jan 10, 2022 08:00 am ET
Ginkgo Bioworks Adopts Inscripta’s Onyx Digital Genome Engineering Platform to Continue Accelerating its Genome Editing Throughput
Inscripta, the digital genome engineering company, today announced that Ginkgo Bioworks (NYSE: DNA), th
Jan 10, 2022 07:00 am ET
Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Generation Gene Therapy Capsids
Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Ginkgo Bioworks (NYSE: DNA), the...
Jan 10, 2022 06:00 am ET
Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Generation Gene Therapy Capsids
WATERTOWN, Mass. and BOSTON, Jan. 10, 2022 /PRNewswire/ --  Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to develop safer and more effective next-generation gene therapy viral capsids. This partnership leverages the unique platforms of both companies as they seek to develop next-generation viral capsids with improved
Jan 09, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Zillow Group, Ginkgo Bioworks, StoneCo, and Citrix Systems and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Zillow Group, Inc. (NASDAQ: ZG), Ginkgo Bioworks Holdings, Inc. (NYSE: DNA),...
Jan 08, 2022 11:20 am ET
ROSEN, A LEADING AND TRUSTED LAW FIRM, Encourages Ginkgo Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp. Investors with Losses to Secure Counsel Before Important January 18 Deadline in S
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ginkgo Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp. (NYSE: DNA) (NASDAQ: SRNG) between May 11, 2021 and October 5, 2021, both dates...
Jan 06, 2022 06:05 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ginkgo Bioworks Holdings, Inc. - DNA
NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or the "Company") (NYSE: DNA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jan 06, 2022 06:00 am ET
Optimvia and Ginkgo Bioworks Announce Partnership to Manufacture Biosynthetic Heparin
BOSTON and CINCINNATI, Jan. 6, 2022 /PRNewswire/ -- Optimvia, a biotechnology company specializing in engineering enzymes and their cofactors to synthesize complex therapeutic molecules, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a partnership to improve the manufacturing efficiency of biosynthetic heparin, an essential medicine currently produced from industrial animal agriculture. Under the partnership, Optimvia seeks to leverage Ginkgo's cell and enzyme engineering platform, as well as its fermentation process development experti
Jan 05, 2022 10:11 am ET
DNA CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Ginkgo Bioworks Holdings, Inc. Shareholders of Securities Fraud Class Action Lawsuit
RADNOR, Pa., Jan. 5, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Ginkgo Bioworks Holdings, Inc. ("Ginkgo") (NYSE: DNA) f/k/a Soaring Eagle Acquisition Corp. (NASDAQ: SRNG). The action charges Ginkgo with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Ginkgo's materially misleading statements to the public, Ginkgo investors have suffered significant losses.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.